Cisplatin is an anticancer agent that induces renal proximal tubule lesions in many species.
Evaluation of Novel Biomarkers of Nephrotoxicity in Two Strains of Rat Treated With Cisplatin
Toxicologic Pathology, 2010
Open access, peer-reviewed publications ensure that knowledge is a public good. HESI believes that accessible research is critical for equitable engagement, diverse collaboration, and increased interdisciplinary conversation. We strive to achieve open access on all publications, and more than 200 publications from HESI programs have been published in the last decade.
Toxicologic Pathology, 2010
Cisplatin is an anticancer agent that induces renal proximal tubule lesions in many species.
Toxicologic Pathology, 2010
We investigated the kinetics of circulating biomarker elevation, specifically correlated with morphology in acute myocardial injury.
Journal of Pharmacological and Toxicological Methods, 2010
Cardiovascular safety concerns are a significant cause of attrition in the development of new drugs (Lasser et al., 2002).
Journal of Immunotoxicology, 2010
Non-human primates (NHP), particularly macaques, are commonly used in studies conducted to assess toxicity of new pharmaceutical entities.
Journal of Immunotoxicology, 2010
Non-human primates (NHP) are used to best understand and address pharmacology and toxicology obligations for human patients with highest and/or unmet need.
Regulatory Toxicology and Pharmacology, 2010
The Health and Environmental Sciences Institute Protein Allergenicity Technical Committee hosted an international workshop November 16–17, 2009, in Paris, France, with over 60 participants from academia, government, and industry to review and discuss the potential utility of “-omics” technologies for assessing the ...
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.